Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen.
Helicobacter
; 27(4): e12900, 2022 Aug.
Article
in En
| MEDLINE
| ID: mdl-35644041
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Helicobacter pylori
/
Helicobacter Infections
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Helicobacter
Journal subject:
BACTERIOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Japón